AU Patent

AU2019216630A1 — Compositions and methods for inhibiting expression of transthyretin

Assigned to Alnylam Pharmaceuticals Inc · Expires 2019-09-05 · 7y expired

What this patent protects

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of W:\NRPortbl\GHMatters\MICHELES\9399087_1.docx 18/08/17

USPTO Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of W:\NRPortbl\GHMatters\MICHELES\9399087_1.docx 18/08/17

Drugs covered by this patent

Patent Metadata

Patent number
AU2019216630A1
Jurisdiction
AU
Classification
—
Expires
2019-09-05
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.